467 related articles for article (PubMed ID: 33713047)
41. S100A gene family: immune-related prognostic biomarkers and therapeutic targets for low-grade glioma.
Zhang Y; Yang X; Zhu XL; Bai H; Wang ZZ; Zhang JJ; Hao CY; Duan HB
Aging (Albany NY); 2021 Jun; 13(11):15459-15478. PubMed ID: 34148033
[TBL] [Abstract][Full Text] [Related]
42. Acylglycerol kinase functions as an oncogene and an unfavorable prognostic marker of human gliomas.
Liu N; Wang Z; Cheng Y; Zhang P; Wang X; Yang H; Liu H; Zhang Y; Tu Y
Hum Pathol; 2016 Dec; 58():105-112. PubMed ID: 27574811
[TBL] [Abstract][Full Text] [Related]
43. MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status.
Li G; Wang Z; Zhang C; Liu X; Yang F; Sun L; Liang J; Hu H; Liu Y; You G; Bao Z; Zhang W; Wang Z; Jiang T
Dis Markers; 2018; 2018():5975216. PubMed ID: 29887919
[TBL] [Abstract][Full Text] [Related]
44. A multi-omics analysis-based model to predict the prognosis of low-grade gliomas.
Du Z; Jiang Y; Yang Y; Kang X; Yan J; Liu B; Yang M
Sci Rep; 2024 Apr; 14(1):9427. PubMed ID: 38658591
[TBL] [Abstract][Full Text] [Related]
45. B2M overexpression correlates with malignancy and immune signatures in human gliomas.
Zhang H; Cui B; Zhou Y; Wang X; Wu W; Wang Z; Dai Z; Cheng Q; Yang K
Sci Rep; 2021 Mar; 11(1):5045. PubMed ID: 33658560
[TBL] [Abstract][Full Text] [Related]
46. Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients.
Liu Z; Shen F; Wang H; Li A; Wang J; Du L; Liu B; Zhang B; Lian X; Pang B; Liu L; Gao Y
Cell Cycle; 2020 Jul; 19(13):1632-1640. PubMed ID: 32436804
[TBL] [Abstract][Full Text] [Related]
47. Ferroptosis in Low-Grade Glioma: A New Marker for Diagnosis and Prognosis.
Liu Y; Xu Z; Jin T; Xu K; Liu M; Xu H
Med Sci Monit; 2020 Jun; 26():e921947. PubMed ID: 32484805
[TBL] [Abstract][Full Text] [Related]
48. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
49. Clinical and molecular immune characterization of ERBB2 in glioma.
Mei J; Wang T; Xu R; Chen D; Zhang Y
Int Immunopharmacol; 2021 May; 94():107499. PubMed ID: 33640859
[TBL] [Abstract][Full Text] [Related]
50. Establishment of an Immune-Related Gene Signature for Risk Stratification for Patients with Glioma.
He J; Zeng C; Long Y
Comput Math Methods Med; 2021; 2021():2191709. PubMed ID: 34497663
[TBL] [Abstract][Full Text] [Related]
51. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
52. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
53. Downregulation of LUZP2 Is Correlated with Poor Prognosis of Low-Grade Glioma.
Li Y; Deng G; Qi Y; Zhang H; Jiang H; Geng R; Ye Z; Liu B; Chen Q
Biomed Res Int; 2020; 2020():9716720. PubMed ID: 32695826
[TBL] [Abstract][Full Text] [Related]
54. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
[No Abstract] [Full Text] [Related]
55. Expression and Prognostic Role of PANK1 in Glioma.
Zhao Z; Xu X; Ma S; Li L
Comb Chem High Throughput Screen; 2024; 27(5):715-724. PubMed ID: 37138430
[TBL] [Abstract][Full Text] [Related]
56. CAMKK2, Regulated by Promoter Methylation, is a Prognostic Marker in Diffuse Gliomas.
Liu DM; Wang HJ; Han B; Meng XQ; Chen MH; Yang DB; Sun Y; Li YL; Jiang CL
CNS Neurosci Ther; 2016 Jun; 22(6):518-24. PubMed ID: 27012733
[TBL] [Abstract][Full Text] [Related]
57. Identification and clinical validation of diverse cell-death patterns-associated prognostic features among low-grade gliomas.
Yang W; Yu H; Lei Q; Pu C; Guo Y; Lin L
Sci Rep; 2024 May; 14(1):11874. PubMed ID: 38789729
[TBL] [Abstract][Full Text] [Related]
58. BCL7A as a novel prognostic biomarker for glioma patients.
Liu J; Gao L; Ji B; Geng R; Chen J; Tao X; Cai Q; Chen Z
J Transl Med; 2021 Aug; 19(1):335. PubMed ID: 34362400
[TBL] [Abstract][Full Text] [Related]
59. The ALDH Family Contributes to Immunocyte Infiltration, Proliferation and Epithelial-Mesenchymal Transformation in Glioma.
Wang Z; Mo Y; Tan Y; Wen Z; Dai Z; Zhang H; Zhang X; Feng S; Liang X; Song T; Cheng Q
Front Immunol; 2021; 12():756606. PubMed ID: 35116021
[TBL] [Abstract][Full Text] [Related]
60. Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.
Mou Y; Zhang L; Liu Z; Song X
BMC Cancer; 2022 Feb; 22(1):215. PubMed ID: 35227235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
